Primary aldosteronism - Part I: Prevalence, screening, and selection of cases for adrenal vein sampling

Journal of Nephrology

Volumn 21, Issue 4, 2008, Pages 447-454

  Rossi, Gian Paolo ^a,b   Seccia, Teresa Maria ^a   Pessina, Achille Cesare ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b UNIVERSITY HOSPITAL OF PADOVA   (Italy)

Author keywords

Aldosterone; Hypertension; Primary aldosteronism; Renal damage; Renin

Indexed keywords

ALDOSTERONE; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOXAZOSIN; EPLERENONE; FLUDROCORTISONE; MINERALOCORTICOID ANTAGONIST; POTASSIUM; RENIN; SPIRONOLACTONE;

ADRENALECTOMY; ALDOSTERONE BLOOD LEVEL; ALDOSTERONE RELEASE; ARTICLE; CARDIOVASCULAR RISK; COMBINATION CHEMOTHERAPY; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; DRUG CHOICE; DRUG DOSE REDUCTION; DRUG MECHANISM; DRUG WITHDRAWAL; FALSE POSITIVE RESULT; HUMAN; HYPERTENSION; HYPOKALEMIA; INCIDENCE; INTERMETHOD COMPARISON; KIDNEY INJURY; MONOTHERAPY; PATIENT REFERRAL; PLASMA RENIN ACTIVITY; PREVALENCE; PRIMARY HYPERALDOSTERONISM; PROCESS OPTIMIZATION; SALT LOADING; SCREENING TEST; SENSITIVITY AND SPECIFICITY; ADRENAL GLAND; HYPERALDOSTERONISM; ITALY; MASS SCREENING; METHODOLOGY; PATHOLOGY; PATIENT SELECTION; REVIEW; VASCULARIZATION; VEIN;

ADRENAL GLANDS; HUMANS; HYPERALDOSTERONISM; HYPERTENSION; ITALY; MASS SCREENING; PATIENT SELECTION; PREVALENCE; VEINS;

EID: 52649088378     PISSN: 11218428     EISSN: 17246059     Source Type: Journal    
DOI: None     Document Type: Article

References (65)

1. Fiore C, Calo LA, Colombo L, Grimm CE, Armanini D. History of aldosterone on its 50th birthday. J Nephrol. 2006;19(Suppl 10):S124-S126.
2. Conn JW, Cohen EL, Rovner DR, Nesbit RM. Normokalemic primary aldosteronism: a detectable cause of curable "essential" hypertension. JAMA. 1965;193:200-206.
3. Conn JW, Rovner DR, Cohen EL, Nesbit RM. Normokalemic primary aldosteronism: its masquerade as "essential" hypertension. JAMA. 1966;195:21-26.
4. Conn JW. Primary aldosteronism. In: Genest O, Harnet P, eds. Hypertension: Pathophysiology and Treatment. New York: McGraw-Hill; 1977:768-780.
5. Conn JW. Part I: painting background. Part II: primary aldosteronism, a new clinical syndrome. J Lab Clin Med. 1990;116:253-267.
6. Conn JW. Plasma renin activity in primary aldosteronism. JAMA. 1964;190:222-225.
7. Conn JW. A concluding response. Arch Intern Med. 1969;123:154-155.
8. Rossi GP. Primary aldosteronism: a needle in a haystack or a yellow cab on Fifth Avenue? Curr Hypertens Rep. 2004;6:1-4.
9. Gordon RD, Ziesak MD, Tunny TJ, Stowasser M, Klemm SA. Evidence that primary aldosteronism may not be uncommon: 12% incidence among antihypertensive drug trial volunteers. Clin Exp Pharmacol Physiol. 1993;20:296-298.
10. Anderson GH Jr, Blakeman N, Streeten DH. The effect of age on prevalence of secondary forms of hypertension in 4429 consecutively referred patients. J Hypertens. 1994;12:609-615.
11. Gordon RD, Stowasser M, Tunny TJ, Klemm SA, Rutherford JC. High incidence of primary aldosteronism in 199 patients referred with hypertension. Clin Exp Pharmacol Physiol. 1994;21:315-318.
12. Abdelhamid S, Muller-Lobeck H, Pahl S, et al. Prevalence of adrenal and extra-adrenal Conn syndrome in hypertensive patients. Arch Intern Med. 1996;156:1190-1195.
13. Brown MA, Cramp HA, Zammit VC, Whitworth JA. Primary hyperaldosteronism: a missed diagnosis in 'essential hypertensives'? Aust N Z J Med. 1996;26:533-538.
14. Rossi GP, Rossi E, Pavan E, et al. Screening for primary aldosteronism with a logistic multivariate discriminant analysis. Clin Endocrinol (Oxf). 1998;49:713-723.
15. Mosso L, Fardella C, Montero J, et al. High prevalence of undiagnosed primary hyperaldosteronism among patients with essential hypertension. Rev Med Chil. 1999;127:800-806.
16. Rayner BL, Opie LH, Davidson JS. The aldosterone/renin ratio as a screening test for primary aldosteronism. S Afr Med J. 2000;90:394-400.
17. Loh KC, Koay ES, Khaw MC, Emmanuel SC, Young WF Jr. Prevalence of primary aldosteronism among Asian hypertensive patients in Singapore. J Clin Endocrinol Metab. 2000;85:2854-2859.
18. Denolle T, Hanon O, Mounier-Vehier C, et al. [What tests should be conducted for secondary arterial hypertension in hypertensive patients resistant to treatment?] [article in French]. Arch Mal Coeur Vaiss. 2000;93:1037-1039.
19. Cortes P, Fardella C, Oestreicher E, et al. Excess of mineralocorticoids in essential hypertension: clinical-diagnostic approach. Rev Med Chil. 2000;128:955-961.
20. Nishikawa T, Omura M. Clinical characteristics of primary aldosteronism: its prevalence and comparative studies on various causes of primary aldosteronism in Yokohama Rosai Hospital. Biomed Pharmacother. 2000;54(Suppl 1):83s-85s.
21. Fardella CE, Mosso L, Gomez-Sanchez C, et al. Primary hyperaldosteronism in essential hypertensives: prevalence, biochemical profile, and molecular biology. J Clin Endocrinol Metab. 2000;85:1863-1867.
22. Lim PO, Dow E, Brennan G, Jung RT, MacDonald TM. High prevalence of primary aldosteronism in the Tayside hypertension clinic population. J Hum Hypertens. 2000;14:311-315.
23. Rayner BL, Myers JE, Opie LH, Trinder YA, Davidson JS. Screening for primary aldosteronism: normal ranges for aldosterone and renin in three South African population groups. S Afr Med J. 2001;91:594-599.
24. Calhoun DA, Nishizaka MK, Zaman MA, Thakkar RB, Weissmann P. Hyperaldosteronism among black and white subjects with resistant hypertension. Hypertension. 2002;40:892-896.
25. Schwartz GL, Chapman AB, Boerwinkle E, Kisabeth RM, Turner ST. Screening for primary aldosteronism: implications of an increased plasma aldosterone/renin ratio. Clin Chem. 2002;48:1919-1923.
26. Rossi E, Regolisti G, Negro A, Sani C, Davoli S, Perazzoli F. High prevalence of primary aldosteronism using postcaptopril plasma aldosterone to renin ratio as a screening test among Italian hypertensives. Am J Hypertens. 2002;15(10 Pt 1):896-902.
27. Rossi GP, Bernini G, Caliumi C, et al. A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. J Am Coll Cardiol. 2006;48:2293-2300.
28. Rossi GP, Pessina AC, Heagerty AM. Primary aldosteronism: an update on screening, diagnosis and treatment. J Hypertens. 2008;26:613-621.
29. Fritsch NM, Schiffrin EL. Aldosterone: a risk factor for vascular disease. Curr Hypertens Rep. 2003;5:59-65.
30. Pu Q, Neves MF, Virdis A, Touyz RM, Schiffrin EL. Endothelin antagonism on aldosterone-induced oxidative stress and vascular remodeling. Hypertension. 2003;42:49-55.
31. Brilla CG, Maisch B, Weber KT. Myocardial collagen matrix remodelling in arterial hypertension. Eur Heart J. 1992;13(Suppl D):24-32.
32. Brilla CG, Pick R, Tan LB, Janicki JS, Weber KT. Remodeling of the rat right and left ventricles in experimental hypertension. Circ Res. 1990;67:1355-1364.
33. Catena C, Colussi G, Nadalini E, et al. Cardiovascular outcomes in patients with primary aldosteronism after treatment. Arch Intern Med. 2008;168:80-85.
34. Rocha R, Martin-Berger CL, Yang P, Scherrer R, Delyani J, McMahon E. Selective aldosterone blockade prevents angiotensin II/salt-induced vascular inflammation in the rat heart. Endocrinology. 2002;143:4828-4836.
35. Rocha R, Stier CT Jr, Kifor I, et al. Aldosterone: a mediator of myocardial necrosis and renal arteriopathy. Endocrinology. 2000;141:3871-3878.
36. Rocha R, Funder JW. The pathophysiology of aldosterone in the cardiovascular system. Ann N Y Acad Sci. 2002;970:89-100.
37. Rossi GP, Sacchetto A, Pavan E, Scognamiglio R, Pietra M, Pessina AC. Left ventricular systolic function in primary aldosteronism and hypertension. J Hypertens. 1997;19(Suppl 8):S147-S151.
38. Rossi GP, Sacchetto A, Pavan E, et al. Remodeling of the left ventricle in primary aldosteronism due to Conn's adenoma. Circulation. 1997;95:1471-1478.
39. Muiesan ML, Rizzoni D, Salvetti M, et al. Structural changes in small resistance arteries and left ventricular geometry in patients with primary and secondary hypertension. J Hypertens. 2002;20:1439-1444.
40. Rizzoni D, Muiesan ML, Porteri E, et al. Relations between cardiac and vascular structure in patients with primary and secondary hypertension. J Am Coll Cardiol. 1998;32:985-992.
41. Kozakova M, Buralli S, Palombo C, et al. Myocardial ultrasonic backscatter in hypertension: relation to aldosterone and endothelin. Hypertension. 2003;41:230-236.
42. Nishimura M, Uzu T, Fujii T, et al. Cardiovascular complications in patients with primary aldosteronism. Am J Kidney Dis. 1999;33:261-266.
43. Takeda R, Matsubara T, Miyamori I, Hatakeyama H, Morise T. Vascular complications in patients with aldosterone producing adenoma in Japan: comparative study with essential hypertension. The Research Committee of Disorders of Adrenal Hormones in Japan. J Endocrinol Invest. 1995;18:370-373.
44. Halimi JM, Mimran A. Albuminuria in untreated patients with primary aldosteronism or essential hypertension. J Hypertens. 1995;13:1801-1802.
45. Rossi GP, Bernini G, Desideri G, et al. Renal damage in primary aldosteronism: results of the PAPY Study. Hypertension. 2006;48:232-238.
46. Sechi LA, Novello M, Lapenna R, et al. Long-term renal outcomes in patients with primary aldosteronism. JAMA. 2006;295:2638-2645.
47. Sawka AM, Young WF, Thompson GB, et al. Primary aldosteronism: factors associated with normalization of blood pressure after surgery. Ann Intern Med. 2001;135:258-261.
48. Biglieri EG, Kater CE, Arteaga EE. Primary aldosteronism is comprised of primary adrenal hyperplasia and adenoma. J Hypertens Suppl. 1984;2:S259-S261.
49. Rossi GP, Pessina AC, Mantero F. More fuel to the debate on the "epidemics of primary aldosteronism". Hypertension. 2008; 51:e1-e2.
50. Mulatero P, Dluhy RG, Giacchetti G, Boscaro M, Veglio F, Stewart PM. Diagnosis of primary aldosteronism: from screening to subtype differentiation. Trends Endocrinol Metab. 2005;16:114-119.
51. Rossi GP, Seccia TM, Pessina AC. Clinical use of laboratory tests for the identification of secondary forms of arterial hypertension. Crit Rev Clin Lab Sci. 2007;44:1-85.
52. Sealey JE, Gordon RD, Mantero F. Plasma renin and aldosterone measurements in low renin hypertensive states. Trends Endocrinol Metab. 2005;16:86-91.
53. Rossi GP, Sacchetto A, Chiesura-Corona M, et al. Identification of the etiology of primary aldosteronism with adrenal vein sampling in patients with equivocal computed tomography and magnetic resonance findings: results in 104 consecutive cases. J Clin Endocrinol Metab. 2001;86:1083-1090.
54. Stowasser M, Gordon RD, Gunasekera TG, et al. High rate of detection of primary aldosteronism, including surgically treatable forms, after 'non-selective' screening of hypertensive patients. J Hypertens. 2003;21:2149-2157.
55. Stowasser M, Gordon RD, Rutherford JC, Nikwan NZ, Daunt N, Slater GJ. Diagnosis and management of primary aldosteronism. J Renin Angiotensin Aldosterone Syst. 2001;2:156-169.
56. Mulatero P, Rabbia F, Milan A, et al. Drug effects on aldosterone/plasma renin activity ratio in primary aldosteronism. Hypertension. 2002;40:897-902.
57. Stowasser M, Gordon RD, Rutherford JC, Nikwan NZ, Daunt N, Slater GJ. Diagnosis and management of primary aldosteronism. J Renin Angiotensin Aldosterone Syst. 2001;2:156-169.
58. Agharazii M, Douville P, Grose JH, Lebel M. Captopril suppression versus salt loading in confirming primary aldosteronism. Hypertension. 2001;37:1440-1443.
59. Holland OB, Brown H, Kuhnert L, Fairchild C, Risk M, Gomez-Sanchez CE. Further evaluation of saline infusion for the diagnosis of primary aldosteronism. Hypertension. 1984;6:717-723.
60. Castro OL, Yu X, Kem DC. Diagnostic value of the post-captopril test in primary aldosteronism. Hypertension. 2002;39:935-938.
61. Rossi GP, Belfiore A, Bernini G, et al. Comparison of the captopril and the saline infusion test for excluding aldosterone-producing adenoma. Hypertension. 2007;50:424-431.
62. Rossi GP, Belfiore A, Bernini G, et al. Prospective evaluation of the saline infusion test for excluding primary aldosteronism due to aldosterone-producing adenoma. J Hypertens. 2007;25:1433-1442.
63. Irony I, Kater CE, Biglieri EG, Shackleton CH. Correctable subsets of primary aldosteronism: primary adrenal hyperplasia and renin responsive adenoma. Am J Hypertens. 1990;3:576-582.
64. Tanemoto M, Honkura K, Abe M, Satoh F, Abe T, Ito S. Aldosterone-producing adenoma accompanied with renal artery stenosis. J Nephrol. 2006;19:540-542.
65. Rossi GP, Seccia TM, Pessina AC. Primary aldosteronism: Part II: subtype differentiation and treatment. J Nephrol 2008;21:455-462.